What brands are the COVID-19 vaccines that China is playing？ Which COVID-19 vaccine is more effective？
Recently, COVID-19’s vaccination in China has ushered in two good news. The first is that the number of vaccinations has exceeded 800 million, and the second is that another inactivated vaccine from Covid-19 has been approved for use. So, up to now, how many brands of China COVID-19 vaccine are there? Which effect is better? Let’s answer one or two questions for you by Xiaobian!
1. How many brands of China COVID-19 vaccine are there?
By the end of early June, there were seven major brands of China COVID-19 vaccine, namely Beijing Bio-COVID-19 Vaccine, Kexing Zhongxingguan Vaccine, Wuhan Bio-COVID-19 Vaccine, Kangxinuo COVID-19 Vaccine, Zhifei COVID-19 Vaccine, Kangtai COVID-19 Vaccine and COVID-19 Vaccine of Institute of Biology, Chinese Academy of Medical Sciences. Details of each brand are summarized as follows:
1. Beijing Biological COVID-19 Vaccine
① R&D unit: Beijing Institute of Biological Products Co., Ltd.
② vaccine name: Covid-19 inactivated vaccine (Vero cell)
③ Age of use: 18 years or older.
④ Immunization program: 2 doses.
⑤ Approval type: WHO emergency use
⑥ Effectiveness: The prevention of symptoms and hospitalization was 79%.
2. Kexing Zhongxin Crown Vaccine
① Research and development unit: Beijing Kexing Zhongwei Biotechnology Co., Ltd.
② vaccine name: Covid-19 inactivated vaccine (Vero cell)
③ Age of use: 18 years or older.
④ Immunization program: 2 doses.
⑤ Approval type: WHO emergency use
⑥ Effectiveness: The prevention of symptoms was 51% and the prevention of hospitalization was 100%.
3. Wuhan Biological COVID-19 Vaccine
① R&D unit: Wuhan Institute of Biological Products Co., Ltd.
② vaccine name: Covid-19 inactivated vaccine (Vero cell)
③ Age of use: 18 years or older.
④ Immunization program: 2 doses.
⑤ Approval Type: Conditional Listing in China
⑥ Effectiveness: The total protection effectiveness is 72.51%, and the prevention of moderate and severe diseases is 100%.
4. Kangxinuo COVID-19 vaccine
① R&D units: Institute of Biological Engineering, Institute of Military Science, Kangxinuo Bio-stock Company.
② vaccine name: recombinant novel coronavirus vaccine (adenovirus type 5)
③ Age of use: 18 years or older.
④ Immunization program: 1 dose.
⑤ Approval Type: Conditional Listing in China
⑥ Effectiveness: The total protection effectiveness is 65.7%, and the prevention of severe illness is 90.98%.
5. Zhifei COVID-19 vaccine
① R&D unit: Anhui Zhifei Technology Co., Ltd.
② vaccine name: recombinant novel coronavirus vaccine (CHO cell)
③ Age of use: 18 years or older.
④ Immunization program: 3 doses.
⑤ Approval type: domestic emergency use
6. Kangtai COVID-19 vaccine
① Research and development unit: Shenzhen Kangtai Biological Products Co., Ltd.
② vaccine name: Covid-19 inactivated vaccine (Vero cell)
③ Age of use: 18 years or older.
④ Immunization program: 2 doses.
⑤ Approval type: domestic emergency use
7. Medical biological COVID-19 vaccine
① R&D unit: Institute of Medical Biology, Chinese Academy of Medical Sciences
② vaccine name: Covid-19 inactivated vaccine (Vero cell)
③ Age of use: 18 years or older.
④ Immunization program: 2 doses.
⑤ Approval type: domestic emergency use
The emergency use of WHO means that it has been approved by the World Health Organization (WHO) to be included in the emergency use list. Conditional listing in China is to conduct emergency review and approval according to relevant regulations and special drug approval procedures, and conditionally approve listing registration applications. In case of particularly serious public health emergencies or other emergencies that seriously threaten public health in domestic emergency use, it can be used for emergency use within a certain scope and time limit with the consent of the drug supervision and administration department of the State Council.
Second, COVID-19 vaccine which effect is better?
1. Beijing Biological COVID-19 Vaccine
The WHO Advisory Expert Group on Immunization Strategy has completed the review of the vaccine. A large multinational phase III clinical trial showed that the effective rate of preventing symptomatic Covid-19 infection 14 days or longer after vaccination was 79%, and the effective rate of preventing hospitalization was 79%. Because there are very few elderly people over 60 who participate in clinical trials, it is impossible to estimate the effectiveness of this age group; Despite this, WHO does not recommend setting an upper age limit for the vaccine, because preliminary data and immunogenicity auxiliary data indicate that the vaccine may also have a protective effect on the elderly.
2. Kexing Zhongxin Crown Vaccine
The WHO Advisory Expert Group on Immunization Strategy has completed the review of the vaccine. The results of vaccine efficacy research show that the vaccine can prevent 51% of the vaccinated people from developing disease symptoms, and prevent 100% of the research population from developing severe Covid-19’s disease and hospitalization. Because there are very few elderly people over 60 who participate in clinical trials, it is impossible to estimate the effectiveness of this age group; Nevertheless, WHO does not recommend setting an upper age limit for the vaccine, because the data and immunogenicity auxiliary data collected during the subsequent use in many countries indicate that the vaccine may also have a protective effect on the elderly.
3. Wuhan Biological COVID-19 Vaccine
The interim analysis data of the international multi-center, randomized, double-blind, placebo-controlled phase III clinical trial in the United Arab Emirates and other countries showed that the protection rate of the vaccine against the diagnosed moderate and severe diseases reached 100%, and the total protection efficacy was 72.51%. The vaccine is currently awaiting approval from WHO.
4. Kangxinuo COVID-19 vaccine
The data of Phase III clinical trials of more than 40,000 subjects in 78 clinical research centers in five countries (Mexican, Russian, Pakistani, Argentine and Chilean) showed that the protective effect of the vaccine on severe COVID-19 was 90.98% after 28 days of single-needle vaccination, and the overall protective effect was 65.7%. The vaccine is currently awaiting approval from WHO.
5. Zhifei COVID-19 vaccine
The results of two clinical trials involving 950 healthy adults aged 18-59 in Chongqing, Beijing and Hunan provinces in China showed that 76% and 97% of people could produce neutralizing antibodies after two doses and three doses of vaccine respectively. At present, no phase III clinical trial data has been published.
6. Kangtai COVID-19 vaccine
Phase II clinical trials showed that the median GMT of live virus neutralizing antibody in the vaccine group was 131.7 IU/ml 28 days after the 18-59-year-old subjects completed the whole immunization, which indicated that the vaccine could induce a strong antibody response in adults aged 18-59. At present, no phase III clinical trial data has been published.
7. COVID-19 vaccine of Institute of Biology, Chinese Academy of Medical Sciences.
The results of phase ⅰ and ⅱ clinical trials showed that the positive conversion rates of neutralizing antibody and anti-S protein antibody reached 96% and 99.33% respectively 14 days after the whole vaccination. At present, no phase III clinical trial data has been published.
To sum up, every COVID-19 vaccine brand is good and has its own characteristics.
Generally speaking, at present, there are seven COVID-19 vaccines approved by the state in China, each of which has its advantages. Therefore, it is ok to fight any one, and there is no need to wait for any brand of vaccine.